LIV001 / Medytox - LARVOL DELTA

LIV001 in Patients with Mild-to-Moderate Active Ulcerative Colitis (UC) (clinicaltrials.gov) - P1 | N=15 | Not yet recruiting | Sponsor: Liveome Inc.

New P1 trial • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

A Study of LIV001 in Healthy Subjects and Those with Mild-to-Moderate Active Ulcerative Colitis (UC) (clinicaltrials.gov) - P1 | N=38 | Completed | Sponsor: Liveome Inc. | Recruiting ➔ Completed | Trial completion date: Jul 2024 ➔ Mar 2024

Trial completion • Trial completion date • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Liviome "Inflammatory Bowel Disease New Drug 'LIV001', Approved for Phase 1b in Europe" [Google translation] (HIT News) - "Medytox...and its affiliate Liviome...announced on the 19th that they received approval from the European Medicines Agency (EMA) for the European phase 1b clinical trial of 'LIV001', a new microbiome drug for the treatment of inflammatory bowel disease."

New P1 trial • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Liveome secures Chinese patent for microbial gene therapy platform and IBD treatment (Korea Biomedical Review) - "Liveome, a subsidiary of Medytox specializing in new drug development, said it registered a patent in China for its microbial gene therapy development platform and LIV001, an inflammatory bowel disease (IBD) treatment...Given the rising prevalence of IBD in North America, Europe, and now Asia, securing a patent in China further solidifies Liveome's strategic positioning for global commercialization....LIV001, a microbial gene therapy developed using this platform, introduces a peptide VIP gene with immunomodulatory properties into microorganisms to treat IBD."

Patent • Immunology • Inflammation • Inflammatory Bowel Disease

Liveome completes P1 study into gene-recombinant microbiome drug for inflammatory bowel disease in Australia (Korea Biomedical Review) - P1 | N=36 | NCT05975047 | Sponsor: Liveome Inc. | "Liveome, an affiliate of Medytox, said it completed the phase 1 clinical trial in Australia for its gene-recombinant microbiome drug, LIV001....Following a review by the Safety Review Committee, LIV001 was found to have a favorable safety and tolerability profile. Based on these results, Liveome intends to proceed with multinational clinical trials to evaluate the efficacy of LIV001 further."

P1 data • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

A Study of LIV001 in Healthy Subjects and Those With Mild-to-Moderate Active Ulcerative Colitis (UC) (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: Liveome Inc. | Not yet recruiting ➔ Recruiting | Phase classification: P1a/1b ➔ P1

Enrollment open • Phase classification • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

A Study of LIV001 in Healthy Subjects and Those With Mild-to-Moderate Active Ulcerative Colitis (UC) (clinicaltrials.gov) - P1a/1b | N=36 | Not yet recruiting | Sponsor: Liveome Inc.

New P1 trial • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Liveome draws ￦7billion Series A funding (Korea Biomedical Review) - "Liveome, a subsidiary of Medytox, said that it successfully attracted 7 billion won ($5.6 million) Series A funding from Lindeman Asia Investment Group....With the funding, Liveome plans to spur clinical trials for LIV001, its inflammatory bowel disease candidate, and speed up the R&D of follow-up pipelines such as anticancer drugs....Liveome plans to complete the non-clinical trial of LIV001 this year and enter global clinical trials in 2023."

Financing • New trial • Immunology • Inflammatory Bowel Disease

SGS : Partnership with Liveome in New IBD Drug Development Project (Market Screener) - "SGS is pleased to announce that we are partnering with Liveome on a major project to develop and commercialize an inflammatory bowel disease (IBD) candidate, LIV001....We have signed a contract with Korean drug development specialist Liveome for the formulation, development and clinical manufacture of a targeted release formulation containing lyophilized microbial cells suitable for phase one clinical trials. The drug substance is being supplied by Australia-based Luina Bio."

Licensing / partnership • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease

Liveome to develop bowel disease drug with 2 foreign CDMOs (Korea Biomedical Review) - "Liveome, a subsidiary of Medytox, has signed contract development and manufacturing organization (CDMO) contracts with Australia’s Luina Bio and U.K.’s Quay Pharma to develop an inflammatory bowel disease candidate, LIV001...'The company aims to complete a nonclinical toxicity test this year and start a global clinical trial by 2023.'"

Licensing / partnership • New trial • Inflammatory Bowel Disease